Premium health check-ups: what really matters
A good check-up is not measured by the number of tests. What the guidelines say, what remains unproven, and four questions that make the difference.
In short
- A test is useful when it can change a decision. The others rarely reassure, and sometimes worry.
- The foundation is well known: blood pressure, lipids, blood sugar, cardiovascular risk and age-appropriate cancer screening.
- Whole-body MRI and “multi-cancer” blood tests are not yet part of it.
So-called premium check-ups are often presented as a list: twenty, forty, sometimes sixty tests. Length reassures. Yet it says little about quality. In medicine, a test is worth the decision it informs: to treat, to monitor, or to do nothing, knowingly.
The trap of “seeing everything”
The more you look, the more you find. A kidney cyst, a thyroid nodule, a small spot on the liver: such incidental findings are common and usually harmless. But once written in a report, they call for further tests, sometimes a biopsy, and weeks of worry.
This is why, in April 2023, the American College of Radiology stated that there is not enough evidence to recommend whole-body MRI for people without symptoms. The scan is not useless in itself. It is discussed in specific situations, with a physician, rather than offered as a matter of course.
The foundation, according to the guidelines
Ages vary from country to country. A good check-up tells you which guidelines it follows, and why.
Heart and blood vessels
- Blood pressure, measured at rest, more than once.
- A lipid profile, and blood sugar or glycated haemoglobin.
- Ten-year cardiovascular risk, calculated with a recognised tool such as SCORE2 in Europe.
- Lipoprotein(a), at least once in a lifetime. The 2019 European guidelines suggest it: this risk factor is largely inherited and does not show on a standard lipid profile.
Cancer screening
- Colon and rectum. From 45 under US guidelines; from 50 to 74 in European programmes.
- Breast. A mammogram every two years from 40 under the 2024 US guidelines; from 45 to 74 under the 2022 European recommendation.
- Cervix. HPV testing, at the interval set in your country.
- Lung. A yearly low-dose CT scan for current and former heavy smokers, aged 50 to 80 under US criteria.
- Prostate. PSA testing between 55 and 69 is decided with the physician, after weighing its benefits and harms.
What is decided case by case
- Coronary calcium score. A scan without contrast that measures calcium in the heart’s arteries. The 2019 US guidelines consider it useful when risk is intermediate and the decision to treat is uncertain.
- Fitness. An exercise test, with or without VO2max. In a 2018 study of 122,007 patients, low cardiorespiratory fitness was associated with a risk of death comparable to, or greater than, that of smoking or diabetes.
- Abdominal aorta. A single ultrasound for men aged 65 to 75 who have ever smoked.
- Bones. A bone density scan, depending on age, menopause and current treatment.
The ICI verdict
Blood pressure, lipids, blood sugar, ten-year cardiovascular risk, lipoprotein(a) once, age-appropriate cancer screening, a measure of fitness.
Blood tests for the early detection of several cancers. In the UK NHS-Galleri trial (more than 142,000 participants, results presented in May 2026), the primary goal, fewer cancers found at stages 3 and 4, was not met. Stage 4 cancers were, however, less frequent in the second and third rounds. The effect on mortality is not yet known.
Whole-body MRI without symptoms; “biological age” and epigenetic clocks used to guide a medical decision; panels of dozens of markers with no specific question behind them.
Four questions to ask before you book
- Why this test, for me?
- Which guidelines do you follow, and for what age?
- Who will explain the results, in person, and in which language?
- If something is found, who calls me, how soon, and at what cost?
Torn between several check-ups? That is exactly what the Curation is for.
Sources
- American College of Radiology, ACR Statement on Screening Total Body MRI, 17 April 2023
- Mach F. et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias, European Heart Journal, 2020
- US Preventive Services Task Force, Breast Cancer: Screening, April 2024
- US Preventive Services Task Force, Colorectal Cancer: Screening, May 2021
- US Preventive Services Task Force, Lung Cancer: Screening, March 2021
- US Preventive Services Task Force, Prostate Cancer: Screening, May 2018
- US Preventive Services Task Force, Abdominal Aortic Aneurysm: Screening, December 2019
- European Commission, new Council recommendation on cancer screening, 9 December 2022
- Arnett D.K. et al., 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, Circulation, 2019
- Mandsager K. et al., Association of Cardiorespiratory Fitness With Long-term Mortality, JAMA Network Open, 2018
- Queen Mary University of London, First results from NHS-Galleri trial, 30 May 2026
Reviewed and approved by Rahima Khirennas, physician by training, on 5 November 2026.
For information only; not a substitute for medical advice.
Editorial responsibility: Infinite Care International LLC.